

# Lynne I Wagner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2243771/publications.pdf>

Version: 2024-02-01

118  
papers

7,169  
citations

147801

31  
h-index

60623

81  
g-index

120  
all docs

120  
docs citations

120  
times ranked

10088  
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (E2108). <i>Journal of Clinical Oncology</i> , 2022, 40, 978-987.	1.6	86
2	A Multi-step Approach to Adapting a Mind-Body Resiliency Intervention for Fear of Cancer Recurrence and Uncertainty in Survivorship (IN FOCUS). <i>Global Advances in Health and Medicine</i> , 2022, 11, 216495612210746.	1.6	4
3	Linking Structural Racism and Discrimination and Breast Cancer Outcomes: A Social Genomics Approach. <i>Journal of Clinical Oncology</i> , 2022, 40, 1407-1413.	1.6	17
4	Facilitators and barriers to reducing chemotherapy for early-stage breast cancer: a qualitative analysis of interviews with patients and patient advocates. <i>BMC Cancer</i> , 2022, 22, 141.	2.6	5
5	Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor-Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation. <i>JAMA Oncology</i> , 2022, 8, 579.	7.1	27
6	Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients. <i>Blood Cancer Journal</i> , 2022, 12, 53.	6.2	4
7	A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152). <i>Cancer</i> , 2022, 128, 1381-1391.	4.1	11
8	Association Between Surgery Preference and Receipt in Ductal Carcinoma In Situ After Breast Magnetic Resonance Imaging. <i>JAMA Network Open</i> , 2022, 5, e2210331.	5.9	3
9	Association between an electronic health record (EHR)-embedded frailty index and survival among older adults receiving cancer chemotherapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 12009-12009.	1.6	5
10	Characteristics of long-surviving patients with multiple myeloma: Over 12 years of follow-up in the Connect MM Registry. <i>Journal of Clinical Oncology</i> , 2022, 40, 8027-8027.	1.6	1
11	Social Genomics as a Framework for Understanding Health Disparities Among Adolescent and Young Adult Cancer Survivors: A Commentary. <i>JCO Precision Oncology</i> , 2022, , .	3.0	3
12	Simulating Colorectal Cancer Trials Using Real-World Data. <i>JCO Clinical Cancer Informatics</i> , 2022, , .	2.1	0
13	Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect <sup>®</sup> MM Registry. <i>British Journal of Haematology</i> , 2021, 193, 93-100.	2.5	4
14	Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 390-399.	6.3	62
15	Impact of insurance and neighborhood socioeconomic status on clinical outcomes in therapeutic clinical trials for breast cancer. <i>Cancer Medicine</i> , 2021, 10, 45-52.	2.8	11
16	Patient-Reported Outcomes Bridge an Important Gap in Identifying Risk for Early Endocrine Therapy Discontinuation. <i>Journal of the National Cancer Institute</i> , 2021, 113, 945-947.	6.3	6
17	Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG-ACRIN TAILORx trial. <i>Cancer</i> , 2021, 127, 2545-2552.	4.1	20
18	Targeted eHealth Intervention to Reduce Breast Cancer Survivors' Fear of Recurrence: Results From the ForTitude Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1495-1505.	6.3	32

#	ARTICLE	IF	CITATIONS
19	Patient perspectives on chemotherapy de-escalation in breast cancer. <i>Cancer Medicine</i> , 2021, 10, 3288-3298.	2.8	16
20	Social determinants of health, genetic ancestry, and mortality in ECOG-ACRIN E5103. <i>Journal of Clinical Oncology</i> , 2021, 39, 6527-6527.	1.6	2
21	Psychological Treatment for Patients Receiving Radiation: Results of NRG Oncology/RTOG 0841. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 962-972.	0.8	2
22	Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect <sup>®</sup> MM Registry. <i>Blood Cancer Journal</i> , 2021, 11, 134.	6.2	5
23	Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy. <i>JAMA Oncology</i> , 2021, 7, 1196.	7.1	13
24	Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. <i>Journal of Clinical Oncology</i> , 2021, 39, 2539-2551.	1.6	78
25	Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	12
26	Reply to T. Shimoi et al and Y. Shimanuki et al. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01905.	1.6	3
27	Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). <i>Radiology</i> , 2021, 301, 66-77.	7.3	17
28	In Reply to Al-Rashdan. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 578.	0.8	0
29	Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy. <i>Cancer</i> , 2021, , .	4.1	3
30	Patient-Reported Testing Burden of Breast Magnetic Resonance Imaging Among Women With Ductal Carcinoma In Situ. <i>JAMA Network Open</i> , 2021, 4, e2129697.	5.9	6
31	Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events. <i>Cancer</i> , 2021, 127, 4546-4556.	4.1	3
32	Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the Connect <sup>®</sup> Multiple Myeloma (MM) Disease Registry. <i>Blood</i> , 2021, 138, 117-117.	1.4	2
33	Quality of Life in Patients &lt;=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912. <i>Blood</i> , 2021, 138, 1562-1562.	1.4	0
34	Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy. <i>JAMA Oncology</i> , 2020, 6, 367.	7.1	100
35	Connect MM Registry as a national reference for United States multiple myeloma patients. <i>Cancer Medicine</i> , 2020, 9, 35-42.	2.8	14
36	Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 272-276.	0.4	16

#	ARTICLE	IF	CITATIONS
37	Development and refinement of FoRtitude: An eHealth intervention to reduce fear of recurrence among breast cancer survivors. <i>Psycho-Oncology</i> , 2020, 29, 227-231.	2.3	9
38	Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis. <i>Cancer</i> , 2020, 126, 4332-4340.	4.1	18
39	Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial. <i>Cancer Medicine</i> , 2020, 9, 7511-7523.	2.8	8
40	Patient Health Questionnaire-9 scores do not accurately estimate depression prevalence: individual participant data meta-analysis. <i>Journal of Clinical Epidemiology</i> , 2020, 122, 115-128.e1.	5.0	113
41	Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. <i>Journal of Clinical Oncology</i> , 2020, 38, 1875-1886.	1.6	59
42	Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect <sup>®</sup> MM Registry. <i>Blood</i> , 2020, 136, 49-50.	1.4	2
43	Early discontinuation to adjuvant endocrine therapy in the ECOG-ACRIN TAILORx Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 7004-7004.	1.6	1
44	Predictive value of bother by side effects of treatment prior to protocol therapy for early treatment discontinuation in clinical trials. <i>Journal of Clinical Oncology</i> , 2020, 38, e19132-e19132.	1.6	3
45	Increase in side effect bother was associated with early treatment discontinuation in a clinical trial among multiple myeloma patients. <i>Journal of Clinical Oncology</i> , 2020, 38, e19136-e19136.	1.6	4
46	Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry. <i>Journal of Clinical Oncology</i> , 2020, 38, 8518-8518.	1.6	1
47	A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 54.	1.9	1
48	Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study. <i>Blood</i> , 2020, 136, 45-46.	1.4	0
49	Development of a prognostic model for overall survival in multiple myeloma using the Connect <sup>®</sup> MM Patient Registry. <i>British Journal of Haematology</i> , 2019, 187, 602-614.	2.5	11
50	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. <i>Future Oncology</i> , 2019, 15, 1683-1695.	2.4	35
51	Implementing electronic health record-integrated screening of patient-reported symptoms and supportive care needs in a comprehensive cancer center. <i>Cancer</i> , 2019, 125, 4059-4068.	4.1	46
52	Oncology clinical trials and insurance coverage: An update in a tenuous insurance landscape. <i>Cancer</i> , 2019, 125, 3488-3493.	4.1	9
53	Iterative adaptation process for eHealth Mindful Movement and Breathing to improve gynecologic cancer surgery outcomes. <i>Psycho-Oncology</i> , 2019, 28, 1774-1777.	2.3	4
54	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2395-2405.	27.0	349

#	ARTICLE	IF	CITATIONS
55	Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 222-229.	1.6	133
56	Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect <sup>®</sup> MM Registry. <i>Blood</i> , 2019, 134, 3129-3129.	1.4	2
57	E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8001-8001.	1.6	17
58	Effect of t(11;14) on outcomes of patients (pts) with newly diagnosed multiple myeloma (NDMM) in the connect MM registry.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8032-8032.	1.6	2
59	Reproductive health in cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS6649-TPS6649.	1.6	0
60	Understanding and predicting fatigue, cardiovascular (CV) decline, and events after breast cancer treatment (UPBEAT): A prospective cardio-oncology study.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS11634-TPS11634.	1.6	0
61	Coping Among Breast Cancer Survivors: A Confirmatory Factor Analysis of the Brief COPE. <i>Journal of Nursing Measurement</i> , 2019, 27, 259-276.	0.3	16
62	Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect <sup>®</sup> MM Registry. <i>Blood</i> , 2019, 134, 1843-1843.	1.4	0
63	Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03). <i>Breast Cancer Research and Treatment</i> , 2018, 169, 537-548.	2.5	58
64	Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial. <i>Supportive Care in Cancer</i> , 2018, 26, 1889-1895.	2.2	6
65	Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. <i>Blood Advances</i> , 2018, 2, 1608-1615.	5.2	28
66	Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 480-485.e3.	0.4	27
67	Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect <sup>®</sup> MM Registry. <i>Annals of Hematology</i> , 2018, 97, 2425-2436.	1.8	33
68	Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry. <i>Clinical Therapeutics</i> , 2018, 40, 1193-1202.e1.	2.5	10
69	Hippocampal functional connectivity is related to self-reported cognitive concerns in breast cancer patients undergoing adjuvant therapy. <i>NeuroImage: Clinical</i> , 2018, 20, 110-118.	2.7	60
70	Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 111-121.	27.0	1,558
71	Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on Lenalidomide Maintenance Therapy: Results from the Connect <sup>®</sup> MM Registry. <i>Blood</i> , 2018, 132, 3232-3232.	1.4	2
72	Predictors of long-term survival in newly diagnosed multiple myeloma (NDMM) patients (pts) enrolled in the Connect MM registry.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8037-8037.	1.6	1

#	ARTICLE	IF	CITATIONS
73	Treatment (tx) journeys in newly diagnosed multiple myeloma (NDMM) patients (pts): Results from the Connect MM Registry.. Journal of Clinical Oncology, 2018, 36, 8041-8041.	1.6	2
74	Development of an eHealth System to Capture and Analyze Patient Sensor and Self-Report Data: Mixed-Methods Assessment of Potential Applications to Improve Cancer Care Delivery. JMIR Medical Informatics, 2018, 6, e46.	2.6	11
75	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. Journal of Clinical Oncology, 2018, 36, TPS4597-TPS4597.	1.6	0
76	E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx” ECOG-ACRIN Cancer Research Group. Journal of Clinical Oncology, 2017, 35, 490-497.	1.6	359
77	Coping strategies tailored to the management of fear of recurrence and adaptation for Ehealth delivery: The FoRtitude intervention. Cancer, 2017, 123, 906-910.	4.1	21
78	Subtle hippocampal deformities in breast cancer survivors with reduced episodic memory and self-reported cognitive concerns. NeuroImage: Clinical, 2017, 14, 685-691.	2.7	36
79	Screening for depression in cancer patients receiving radiotherapy: Feasibility and identification of effective tools in the NRG Oncology RTOG 0841 trial. Cancer, 2017, 123, 485-493.	4.1	24
80	Impact of t(11;14) on outcomes in African American (AA) and non-AA (NAA) patients (Pts) with newly diagnosed multiple myeloma (NDMM): Connect MM registry.. Journal of Clinical Oncology, 2017, 35, 8023-8023.	1.6	3
81	Randomized trial of cisplatin and etoposide in combination with veliparib or placebo for extensive stage small cell lung cancer: ECOG-ACRIN 2511 study.. Journal of Clinical Oncology, 2017, 35, 8505-8505.	1.6	6
82	Harmonization of patient-reported outcomes into EHRs at four cancer hospital outpatient clinics for patient care and quality assessment.. Journal of Clinical Oncology, 2017, 35, 129-129.	1.6	2
83	Next steps for adolescent and young adult oncology workshop: An update on progress and recommendations for the future. Cancer, 2016, 122, 988-999.	4.1	158
84	Care for a Patient With Cancer As a Project: Management of Complex Task Interdependence in Cancer Care Delivery. Journal of Oncology Practice, 2016, 12, 1101-1113.	2.5	25
85	Reduced prefrontal activation during working and long-term memory tasks and impaired patient-reported cognition among cancer survivors postchemotherapy compared with healthy controls. Cancer, 2016, 122, 258-268.	4.1	28
86	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 22	13.7	529
87	E3311 trial of transoral surgery for oropharynx cancer: Implementation of a novel surgeon credentialing and quality assurance process.. Journal of Clinical Oncology, 2016, 34, 6054-6054.	1.6	6
88	Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408).. Journal of Clinical Oncology, 2016, 34, 7507-7507.	1.6	5
89	Development and validation of the functional assessment of cancer therapy”antiangiogenesis subscale. Cancer Medicine, 2015, 4, 690-698.	2.8	11
90	Anxiety and Health-Related Quality of Life Among Patients With Low”Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT). Journal of Clinical Oncology, 2015, 33, 740-748.	1.6	36

#	ARTICLE	IF	CITATIONS
91	Bringing <scp>PROMIS</scp> to practice: Brief and precise symptom screening in ambulatory cancer care. <i>Cancer</i> , 2015, 121, 927-934.	4.1	179
92	Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 2005-2014.	27.0	1,146
93	Symptom reduction from IMRT dose deintensification: Results from ECOG 1308 using the Vanderbilt Head and Neck Symptom Survey version 2 (VHSS V2).. <i>Journal of Clinical Oncology</i> , 2015, 33, 6021-6021.	1.6	5
94	Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 403-403.	1.6	24
95	Implementation of distress screening in an oncology setting. <i>Journal of Community and Supportive Oncology</i> , 2015, 13, 423-428.	0.1	18
96	Concordance of patient and caregiver reports in evaluating quality of life in patients with malignant gliomas and an assessment of caregiver burden. <i>Neuro-Oncology Practice</i> , 2014, 1, 47-54.	1.6	23
97	Self-reported cognitive concerns and abilities: two sides of one coin?. <i>Psycho-Oncology</i> , 2014, 23, 1133-1141.	2.3	123
98	The Validity and Utility of the MD Anderson Symptom Inventory in Patients With Prostate Cancer: Evidence From the Symptom Outcomes and Practice Patterns (SOAPP) Data From the Eastern Cooperative Oncology Group. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 41-49.	1.9	31
99	Prospective Longitudinal Evaluation of a Symptom Cluster in Breast Cancer. <i>Journal of Pain and Symptom Management</i> , 2014, 47, 721-730.	1.2	66
100	Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptor-Positive Breast Cancer (E-3193,) Tj ETQq0 0 0 ggBT /Overlock 10 Tf 3948-3958.	1.6	118
101	Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7099-7099.	1.6	3
102	Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, e19554-e19554.	1.6	3
103	E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA6006-LBA6006.	1.6	6
104	E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA6006-LBA6006.	1.6	26
105	Factors associated with loss of employment among metastatic patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6585-6585.	1.6	0
106	Project onward: an innovative e-health intervention for cancer survivors. <i>Psycho-Oncology</i> , 2013, 22, 947-951.	2.3	77
107	The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). <i>Supportive Care in Cancer</i> , 2013, 21, 1033-1041.	2.2	37
108	Distress Management. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 190-209.	4.9	275

#	ARTICLE	IF	CITATIONS
109	Using the Science of Psychosocial Care to Implement the New American College of Surgeons Commission on Cancer Distress Screening Standard. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 214-221.	4.9	66
110	E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 6005-6005.	1.6	19
111	Development and validation of the functional assessment of cancer therapy: Antiangiogenesis (FACT-AntiA).. <i>Journal of Clinical Oncology</i> , 2013, 31, e20527-e20527.	1.6	0
112	A New Quality Standard: The Integration of Psychosocial Care Into Routine Cancer Care. <i>Journal of Clinical Oncology</i> , 2012, 30, 1154-1159.	1.6	146
113	Content Development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): Use of Qualitative and Quantitative Methods for Scale Construction. <i>Journal of Pain and Symptom Management</i> , 2012, 43, 1094-1104.	1.2	45
114	Quality of Life Results From Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Indolent Non-Hodgkin's Lymphoma. <i>Blood</i> , 2012, 120, 235-235.	1.4	0
115	Evaluating the Dimensionality of Perceived Cognitive Function. <i>Journal of Pain and Symptom Management</i> , 2009, 37, 982-995.	1.2	72
116	Evaluation of the Functional Assessment of Cancer Therapy Cognitive Scale with Hematopoietic Stem Cell Transplant Patients. <i>Journal of Pain and Symptom Management</i> , 2007, 33, 13-23.	1.2	98
117	Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. <i>Oncology</i> , 2007, 21, 34-6.	0.5	77
118	Assessing neurocognitive symptoms in cancer patients and controls: psychometric properties of the FACT-Cog3. <i>Current Psychology</i> , 0, , 1.	2.8	4